Biomarkers associated with the likelihood of response to classical chemotherapy were also expressed differentially between the two diseases: TOP2A (TC: 81.4%; OC: 79.6%; and PC: 67.5%; P < 0.001), RRM1 loss (TC: 72.9%; OC: 74.8%; and PC: 83.3%; P = 0.002), and TS loss (TC: 39.1%; OC: 39.2%; and PC: 54.1%; P < 0.001) showed significantly different expression levels when tested with precision IHC among the three cancer types. Here, RRM1 is linked to cancer.